Posted by Michael Wonder on 10 May 2023
Olaparib for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy in adults.
Olaparib (alone or with endocrine therapy) is recommended, within its marketing authorisation, as an option for the adjuvant treatment of HER2 negative high-risk early breast cancer that has been treated with neo-adjuvant or adjuvant chemotherapy in adults with germline BRCA1 or 2 mutations.
